These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 24267401)
1. Optimizing immunoglobulin treatment for patients with primary immunodeficiency disease to prevent pneumonia and infection incidence: review of the current data. Ballow M Ann Allergy Asthma Immunol; 2013 Dec; 111(6 Suppl):S2-5. PubMed ID: 24267401 [TBL] [Abstract][Full Text] [Related]
2. Illustrative cases on individualizing immunoglobulin therapy in primary immunodeficiency disease. Bonagura VR Ann Allergy Asthma Immunol; 2013 Dec; 111(6 Suppl):S10-3. PubMed ID: 24267400 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases. Stein MR; Koterba A; Rodden L; Berger M Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101 [TBL] [Abstract][Full Text] [Related]
4. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Berger M Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330 [TBL] [Abstract][Full Text] [Related]
5. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Orange JS; Grossman WJ; Navickis RJ; Wilkes MM Clin Immunol; 2010 Oct; 137(1):21-30. PubMed ID: 20675197 [TBL] [Abstract][Full Text] [Related]
7. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. Berger M; Murphy E; Riley P; Bergman GE; South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Berger M; Rojavin M; Kiessling P; Zenker O Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644 [TBL] [Abstract][Full Text] [Related]
9. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Shapiro RS Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460 [TBL] [Abstract][Full Text] [Related]
10. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. Bonagura VR J Clin Immunol; 2013 Jan; 33 Suppl 2():S90-4. PubMed ID: 23271459 [TBL] [Abstract][Full Text] [Related]
11. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency. Gupta S; Kobayashi RH; Litzman J; Cherwin L; Hoeller S; Kreuwel H Expert Rev Clin Immunol; 2023 Jan; 19(1):7-17. PubMed ID: 36346032 [TBL] [Abstract][Full Text] [Related]
12. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach. Jolles S; Sleasman JW Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653 [TBL] [Abstract][Full Text] [Related]
13. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. Gardulf A; Nicolay U; Math D; Asensio O; Bernatowska E; Böck A; Costa-Carvalho BT; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Matamoros N; Niehues T; Schmidt S; Schulze I; Borte M J Allergy Clin Immunol; 2004 Oct; 114(4):936-42. PubMed ID: 15480339 [TBL] [Abstract][Full Text] [Related]
14. Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies. Shrestha P; Karmacharya P; Wang Z; Donato A; Joshi AY World Allergy Organ J; 2019 Oct; 12(10):100068. PubMed ID: 31641401 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Fasth A; Nyström J Acta Paediatr; 2007 Oct; 96(10):1474-8. PubMed ID: 17850391 [TBL] [Abstract][Full Text] [Related]
16. Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies. Mallick R; Jolles S; Kanegane H; Agbor-Tarh D; Rojavin M J Clin Immunol; 2018 Nov; 38(8):886-897. PubMed ID: 30465179 [TBL] [Abstract][Full Text] [Related]
17. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders. McCormack PL BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447 [TBL] [Abstract][Full Text] [Related]
18. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction. Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367 [TBL] [Abstract][Full Text] [Related]
19. Delivery of subcutaneous immunoglobulin by rapid "push" infusion for primary immunodeficiency patients in Manitoba: a retrospective review. Walter G; Kalicinsky C; Warrington R; Miguel M; Reyes J; Rubin TS Allergy Asthma Clin Immunol; 2020; 16():34. PubMed ID: 32426003 [TBL] [Abstract][Full Text] [Related]
20. Intravenous and subcutaneous immunoglobulin G replacement therapy. Bonilla FA Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]